NÃºria SabÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7993461/publications.pdf

Version: 2024-02-01

47	2,088	293460	263392
papers	citations	24 h-index	45 g-index

47	47	47	2730
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A comprehensive assessment of long-term SARS-CoV-2â€“specific adaptive immune memory inÂconvalescent COVID-19 Solid Organ Transplant recipients. Kidney International, 2022, 101, 1027-1038.	2.6	10
2	Risk Factors and Outcomes of Acute Graft Pyelonephritis with Bacteremia Due to Multidrug-Resistant Gram-Negative Bacilli among Kidney Transplant Recipients. Journal of Clinical Medicine, 2022, 11, 3165.	1.0	4
3	Efficacy of Î²â€lactam/Î²â€lactamase inhibitors to treat extendedâ€spectrum betaâ€lactamaseâ€producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENTâ€SOT Project). Transplant Infectious Disease, 2021, 23, e13520.	0.7	10
4	Asymptomatic bacteriuria in kidney transplant recipients: to treat or not to treatâ€”that is the question. Clinical Microbiology and Infection, 2021, 27, 319-321.	2.8	3
5	Tuberculosis prevention in patients undergoing kidney transplantation: A nurseâ€led program for screening and treatment. Transplant Infectious Disease, 2021, 23, e13603.	0.7	3
6	SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. American Journal of Transplantation, 2021, 21, 2749-2761.	2.6	46
7	Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study. PLoS ONE, 2021, 16, e0250796.	1.1	17
8	Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study). Mycoses, 2021, 64, 1334-1345.	1.8	12
9	Extra-anatomic aortic bypass for the treatment of a mycotic pseudoaneurysm after liver transplantation for hilar cholangiocarcinoma. Hepatobiliary and Pancreatic Diseases International, 2020, 20, 285-287.	0.6	1
10	Selection criteria of solid organ donors in relation to infectious diseases: A Spanish consensus. Transplantation Reviews, 2020, 34, 100528.	1.2	4
11	Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing. PLoS ONE, 2019, 14, e0219701.	1.1	18
12	Antibiotic Treatment Versus No Treatment for Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Multicenter Randomized Trial. Open Forum Infectious Diseases, 2019, 6, ofz243.	0.4	26
13	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. Nephrology Dialysis Transplantation, 2018, 33, 1661-1668.	0.4	32
14	Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. Journal of Antimicrobial Chemotherapy, 2018, 73, 1104-1106.	1.3	119
15	Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation. Clinical Microbiology and Infection, 2018, 24, 192-198.	2.8	25
16	Management of Ventriculoperitoneal Shunt Infections in Adults: Analysis of Risk Factors Associated With Treatment Failure. Clinical Infectious Diseases, 2017, 64, 989-997.	2.9	46
17	Changing trends in the aetiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study. Transplant International, 2017, 30, 903-913.	0.8	43
18	Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1â€“2, a Randomized Controlled Clinical Trial. Clinical Infectious Diseases, 2017, 64, 829-838.	2.9	96

#	Article	IF	Citations
19	Detection of cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance. Journal of Clinical Virology, 2017, 90, 57-63.	1.6	19
20	Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study. American Journal of Transplantation, 2016, 16, 3220-3234.	2.6	57
21	Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Caseâ€“Control Study. American Journal of Transplantation, 2016, 16, 2148-2157.	2.6	39
22	The Etiology, Incidence, and Impact of Preservation Fluid Contamination during Liver Transplantation. PLoS ONE, 2016, 11, e0160701.	1.1	16
23	Effect of longâ€term prophylaxis in the development of cytomegalovirusâ€specific Tâ€cell immunity in D+/Râ^' solid organ transplant recipients. Transplant Infectious Disease, 2015, 17, 637-646.	0.7	20
24	Extensively Drug-Resistant Pseudomonas aeruginosa Bacteremia in Solid Organ Transplant Recipients. Transplantation, 2015, 99, 616-622.	0.5	54
25	Effect of delaying prophylaxis against CMV in D+/Râ^' solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease. Journal of Infection, 2015, 71, 561-570.	1.7	11
26	Executive summary. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 680-687.	0.3	14
27	Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 679.e1-679.e21.	0.3	29
28	Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter caseâ€“control study. Clinical Microbiology and Infection, 2015, 21, 89-95.	2.8	44
29	Donorâ€transmitted malaria after heart transplant managed successfully with artesunate. Transplant Infectious Disease, 2014, 16, 999-1002.	0.7	16
30	<scp>C</scp>andida arteritis occurring in a liver transplant recipient. Transplant Infectious Disease, 2014, 16, 465-468.	0.7	4
31	Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial. Trials, 2014, 15, 338.	0.7	7
32	Executive summary. Management of influenza infection in solid-organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 528-534.	0.3	2
33	Management of influenza infection in solid-organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 526.e1-526.e20.	0.3	17
34	Risk Factors and Outcomes of Bacteremia Caused by Drug-Resistant ESKAPE Pathogens in Solid-Organ Transplant Recipients. Transplantation, 2013, 96, 843-849.	0.5	133
35	Risk Factors, Clinical Features, and Outcomes of Toxoplasmosis in Solid-Organ Transplant Recipients: A Matched Case-Control Study. Clinical Infectious Diseases, 2012, 54, 355-361.	2.9	132
36	Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transplantation, 2012, 18, 1093-1099.	1.3	38

#	Article	IF	Citations
37	Risk Factors, Clinical Characteristics, and Outcomes of Invasive Fungal Infections in Solid Organ Transplant Recipients. Transplantation Proceedings, 2012, 44, 2682-2685.	0.3	44
38	Clinical Features and Outcomes of Tuberculosis in Solid Organ Transplant Recipients. Transplantation Proceedings, 2012, 44, 2686-2689.	0.3	54
39	Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors. Transplant International, 2012, 25, e78-e82.	0.8	28
40	Effect of statins on outcomes in immunosuppressed patients with bloodstream infection. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 77-82.	1.3	9
41	Clinical features and outcomes of Legionnaires' disease in solid organ transplant recipients. Transplant Infectious Disease, 2009, 11, 78-82.	0.7	38
42	Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clinical Microbiology and Infection, 2009, 15, 1033-1038.	2.8	58
43	Early mortality in patients with community-acquired pneumonia: causes and risk factors. European Respiratory Journal, 2008, 32, 733-739.	3.1	105
44	Clinical Outcomes for Hospitalized Patients with Legionella Pneumonia in the Antigenuria Era: The Influence of Levofloxacin Therapy. Clinical Infectious Diseases, 2005, 40, 794-799.	2.9	129
45	Outpatient Care Compared with Hospitalization for Community-Acquired Pneumonia. Annals of Internal Medicine, 2005, 142, 165.	2.0	211
46	Contribution of a Urinary Antigen Assay (Binax NOW) to the Early Diagnosis of Pneumococcal Pneumonia. Clinical Infectious Diseases, 2004, 38, 222-226.	2.9	182
47	Clinical Diagnosis of Legionella Pneumonia Revisited: Evaluation of the Community-Based Pneumonia Incidence Study Group Scoring System. Clinical Infectious Diseases, 2003, 37, 483-489.	2.9	63